ProMIS Neurosciences advances PMN310 to final dose cohort in Alzheimer's Phase 1b trial

ProMIS Neurosciences Inc.

DSMB unanimously recommends proceeding to third and final dose escalation cohort (20 mg/kg) after safety review.
Cohort 2 fully enrolled; no cases of amyloid-related imaging abnormalities (ARIA) observed to date.
Enrollment of Cohort 3 underway; 6-month interim data expected Q2 2026, final top-line results Q4 2026.
Trial to enroll 128 patients with comprehensive biomarker panel including pTau217, NfL, GFAP, and synaptic markers.
PMN310 holds FDA Fast Track designation; CEO to present at H.C. Wainwright conference on Sept 10, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.